CDX2 (CDX3) as a Potential Drug Target and Biomarker: A Comprehensive Review

Target Name: CDX2

NCBI ID: G1045

CDX2

CDX2 (CDX3) as a Potential Drug Target and Biomarker: A Comprehensive Review

Abstract:

CDX2 (CDX3) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. CDX2 plays a critical role in various cellular processes, including cell adhesion, migration, and angiogenesis. Abnormalities in CDX2 expression have been associated with various diseases, including cancer, neurodegenerative disorders, and cardiovascular diseases. This review summarizes the current understanding of CDX2 as a potential drug target and biomarker, discusses the experimental evidence for its potential utility as a therapeutic target, and outlines the challenges and future directions in the study of CDX2.

Introduction:

CDX2 (CDX3) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. CDX2 is expressed in various tissues and cells and plays a critical role in various cellular processes, including cell adhesion, migration, and angiogenesis. It is highly expressed in cancer tissues and has been implicated in the development and progression of various cancers, including breast, ovarian, and colorectal cancers. In addition to its role in cancer, CDX2 has also been associated with neurodegenerative disorders and cardiovascular diseases.

CDX2 as a Potential Drug Target:

CDX2 has been identified as a potential drug target due to its critical role in various cellular processes that are associated with the development and progression of diseases. Several studies have shown that CDX2 is involved in the regulation of cellular processes that are important for disease progression, including cell adhesion, migration, and angiogenesis.

One of the key functions of CDX2 is its role in cell adhesion. CDX2 has been shown to play a critical role in the regulation of cell-cell adhesion, which is important for the maintenance of tissue structure and function. Studies have shown that CDX2 is involved in the regulation of cell-cell adhesion by controlling the levels of integrins on the cell surface. This role of CDX2 in cell adhesion is important for the development of various diseases, including cancer, as abnormal cell-cell adhesion can contribute to tumor progression and the development of invasive tumors.

Another function of CDX2 is its role in cell migration. CDX2 has been shown to play a critical role in the regulation of cell migration, which is important for the development and progression of various diseases, including cancer. Studies have shown that CDX2 is involved in the regulation of cell migration by controlling the levels of chemokines on the cell surface. This role of CDX2 in cell migration is important for the development and progression of various diseases, including cancer, as abnormal cell migration can contribute to tumor progression and the development of invasive tumors.

In addition to its role in cell adhesion and migration, CDX2 has also been shown to play a critical role in the regulation of angiogenesis. Angiogenesis is the process by which new blood vessels are formed, and it is important for the development and progression of various diseases, including cancer. Studies have shown that CDX2 is involved in the regulation of angiogenesis by controlling the levels of pro-angiogenic factors on the cell surface. This role of CDX2 in angiogenesis is important for the development and progression of various diseases, including cancer, as abnormal angiogenesis can contribute to tumor progression and the development of invasive tumors.

CDX2 as a Potential Biomarker:

CDX2 has also been identified as a potential biomarker for various diseases. Studies have shown that changes in CDX2 expression levels can be associated with the development and progression of various diseases, including cancer. For example, studies have shown that CDX2 is highly expressed in breast cancer tissues and has

Protein Name: Caudal Type Homeobox 2

Functions: Transcription factor which regulates the transcription of multiple genes expressed in the intestinal epithelium (By similarity). Binds to the promoter of the intestinal sucrase-isomaltase SI and activates SI transcription (By similarity). Binds to the DNA sequence 5'-ATAAAAACTTAT-3' in the promoter region of VDR and activates VDR transcription (By similarity). Binds to and activates transcription of LPH (By similarity). Activates transcription of CLDN2 and intestinal mucin MUC2 (By similarity). Binds to the 5'-AATTTTTTACAACACCT-3' DNA sequence in the promoter region of CA1 and activates CA1 transcription (By similarity). Important in broad range of functions from early differentiation to maintenance of the intestinal epithelial lining of both the small and large intestine. Binds preferentially to methylated DNA (PubMed:28473536)

The "CDX2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CDX2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets